PMID- 33126241
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20240402
IS  - 2156-5376 (Electronic)
IS  - 2161-8313 (Print)
IS  - 2161-8313 (Linking)
VI  - 12
IP  - 3
DP  - 2021 Jun 1
TI  - Probiotics Contribute to Glycemic Control in Patients with Type 2 Diabetes 
      Mellitus: A Systematic Review and Meta-Analysis.
PG  - 722-734
LID - 10.1093/advances/nmaa133 [doi]
AB  - This systematic review aimed to evaluate the effectiveness and safety of 
      probiotics for glycemic control in adults with impaired glucose control, 
      including prediabetes and type 2 diabetes mellitus (T2DM). We searched PubMed, 
      Embase, and Cochrane databases, and trial registries up to February 2019. We 
      included randomized controlled trials (RCTs) of participants with prediabetes or 
      T2DM. Eligible trials compared probiotics versus either placebo, no intervention, 
      or comparison probiotics, or compared synbiotics versus prebiotics. Primary 
      outcomes were mean change in fasting blood glucose (FBG) and glycated hemoglobin 
      (HbA1c) from baseline to short term (<12 wk) and long term (>/=12 wk). We performed 
      meta-analyses using the random-effects model. We included 28 RCTs (1947 
      participants). Overall, probiotics reduced FBG more than the placebo/no 
      intervention group with a mean difference (MD) of -12.99 mg/dL (95% CI: -23.55, 
      -2.42; P value: 0.016) over the short term; and -2.99 mg/dL (95% CI: -5.84, 
      -0.13; P value: 0.040) over the long term. There was also some evidence for 
      reduced HbA1c in the probiotics group at both short term (MD: -0.17; 95% CI: 
      -0.37, 0.02; P value: 0.084) and long term (MD: -0.14; 95% CI: -0.34, 0.06; P 
      value: 0.172), however, these did not reach statistical significance possibly 
      because only a few trials reported HbA1c as an outcome. Subgroup analyses showed 
      a greater reduction in HbA1c in participants not receiving insulin therapy than 
      those receiving insulin therapy. Furthermore, the effect of probiotics on the 
      reduction of FBG was more pronounced in participants with FBG >130 mg/dL and 
      those not receiving insulin therapy than their counterparts. Probiotics were also 
      effective in lowering serum cholesterol over the short and long term. In 
      conclusion, we found that probiotics may have a glucose-lowering effect in T2DM 
      participants. The effect appeared to be stronger in participants with poorly 
      controlled diabetes and those not on insulin therapy. Systematic review 
      registration: CRD42019121682.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the 
      American Society for Nutrition.
FAU - Rittiphairoj, Thanitsara
AU  - Rittiphairoj T
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, MD, USA.
AD  - Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn 
      University, Bangkok, Thailand.
FAU - Pongpirul, Krit
AU  - Pongpirul K
AUID- ORCID: 0000-0003-3818-9761
AD  - Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn 
      University, Bangkok, Thailand.
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public 
      Health, Baltimore, MD, USA.
FAU - Janchot, Kantima
AU  - Janchot K
AD  - Panacee Group Co., Ltd, Bangkok, Thailand.
FAU - Mueller, Noel T
AU  - Mueller NT
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, MD, USA.
AD  - Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, 
      USA.
FAU - Li, Tianjing
AU  - Li T
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, MD, USA.
AD  - Department of Ophthalmology, School of Medicine, University of Colorado Anschutz 
      Medical Campus, Aurora, CO, USA.
LA  - eng
GR  - K01 HL141589/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Adv Nutr
JT  - Advances in nutrition (Bethesda, Md.)
JID - 101540874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Glycated Hemoglobin
MH  - Glycemic Control
MH  - Humans
MH  - Insulin
MH  - *Probiotics/therapeutic use
PMC - PMC8166562
OTO - NOTNLM
OT  - glycemic control
OT  - meta-analysis
OT  - probiotics
OT  - systematic review
OT  - type 2 diabetes mellitus
EDAT- 2020/10/31 06:00
MHDA- 2021/06/23 06:00
PMCR- 2021/10/30
CRDT- 2020/10/30 20:16
PHST- 2020/06/15 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2020/10/30 20:16 [entrez]
PHST- 2021/10/30 00:00 [pmc-release]
AID - S2161-8313(22)00101-6 [pii]
AID - nmaa133 [pii]
AID - 10.1093/advances/nmaa133 [doi]
PST - ppublish
SO  - Adv Nutr. 2021 Jun 1;12(3):722-734. doi: 10.1093/advances/nmaa133.